Form 4: Teva Exec. Sells Shares After Option Exercise

Teva Pharmaceutical Industries' Executive VP of European Commercial, Richard Daniell, exercised stock options and subsequently sold a significant number of ordinary shares.

Summary

• Richard Daniell, Executive VP, European Commercial of Teva Pharmaceutical Industries Ltd. (TEVA), reported transactions on December 9, 2025.
• Daniell exercised options to acquire 100,457 Ordinary Shares at an exercise price of $18.61 per share.
• He also exercised options to acquire an additional 15,011 Ordinary Shares at an exercise price of $16.99 per share.
• Concurrently, Daniell sold 115,468 Ordinary Shares at a weighted average price of $28.6757 per share, with individual sales ranging from $28.635 to $28.765.
• Following these transactions, Daniell's direct beneficial ownership of Ordinary Shares stands at 48,384.

Sentiment

Score: 5

Explanation: The filing reports a standard insider transaction (option exercise and sale) which is generally neutral in sentiment. While the executive profited, the sale of all acquired shares prevents a strongly positive interpretation regarding future stock confidence.

Positives

• The executive realized a substantial profit by exercising stock options at lower prices ($18.61 and $16.99) and selling the shares at a significantly higher market price ($28.6757 weighted average).
• The ability to exercise options and sell shares at a profit indicates a positive appreciation in Teva's stock price since the options were granted.

Negatives

• The executive sold all shares acquired through the option exercise, indicating a decision not to increase direct equity exposure to the company at this time.
• Insider selling, even when related to option exercises, can sometimes be perceived by the market as a lack of confidence, although it is often for personal financial planning or tax obligations.

Risks

• Potential negative market perception if investors interpret the insider sale as a signal of reduced confidence, despite it being a common practice for option exercises.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares, which is a common occurrence in the pharmaceutical industry for executive compensation and personal financial management. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: May observe the insider sale as a data point, but it is unlikely to significantly alter investment theses given the routine nature of option exercises and sales for liquidity/tax purposes.

Key Dates

Keywords

TEVA, Form 4, Insider Transaction, Stock Options, Share Sale, Richard Daniell, Beneficial Ownership